Cholera Vaccines March 2023
Cholera Vaccines March 2023
The U.S. Food and Drug Administration (FDA) approved cholera vaccine Vaxchora® (June 2016) is a live attenuated recombinant V. cholerae O1 Inaba Vaccine Strain CVD 103-HgR. The U.S. Centers for Disease Control and Prevention (CDC) published Cholera Vaccine: Recommendations of the Advisory Committee on Immunization Practices for using Emergent BioSolutions Vaxchora vaccine on September 30, 2022. The CDC recommends Vaxchora for adult travelers and the European Medicine Agency (EMA) for young children who visit an area of active cholera transmission.
Cholera Vaccine Availability 2023
The global supply capacity in 2022 was 36 million OCV doses, whereas demand exceeded 70 million, In the first quarter of 2023, 11.7 million doses have been requested (by six countries), of which 2.2 million doses have been shipped. In December 2020, the maker of Vaxchora temporarily stopped producing it. Therefore, Vaxchora is currently unavailable in the U.S. However, in January 2023, Emergent Customer Service indicated via an email that Vaxchora could become available again in mid-2023.
Cholera Vaccines WHO-Qualified
Currently, three World Health Organization (WHO) pre-qualified oral cholera vaccines (OCV): Dukoral®, Shanchol™, and Euvichol®. All three OCVs require two doses for complete protection against cholera for up to three years, while a single dose provides short-term protection. These vaccines are currently available for mass vaccination campaigns through the Global OCV Stockpile, supported by Gavi, the Vaccine Alliance's Cholera Vaccination Campaigns.
Dukoral® is administered with a buffer solution that, for adults, requires 150 ml of clean water. Dukoral can be given to all individuals over the age of 2 years. There must be at least seven days and no more than six weeks between each dose. Children aged 2-5 require a third dose.
Shanchol™ and Euvichol® are essentially the same vaccines produced by two different manufacturers. Therefore, they do not require a buffer solution for administration. They are given to all individuals over the age of one year with a minimum of two weeks delay between each dose of these vaccines.
Vaxchora® is a U.S. FDA-approved live attenuated recombinant V. cholerae O1 Inaba Vaccine Strain CVD 103-HgR.
Cholera Vaccine Access 2023
The International Coordinating Group (ICG) for cholera vaccines was created in 1997 to manage the global stockpile of OVCs. Since its establishment until October 2022, the WHO, UNICEF, and Médecins sans Frontières have facilitated 73 million doses of OCV to 23 countries.
Cholera Vaccine Dosage 2023
The ICG announced on October 19, 2022, a temporary suspension of the standard two-dose vaccination regimen in cholera outbreak response campaigns, deploying a single-dose vaccination approach in 2023.
Cholera Vaccine News 2023
March 22, 2023 - The WHO published - Multi-country outbreak of cholera, External situation report #1.
February 17, 2023 - @WHOAFRO tweeted that 719,241 doses of OCVs have arrived in Mozambique to prepare vaccination campaigns in the coming weeks for provinces most affected by the cholera outbreak.
February 11, 2023 - The WHO announced it provides guidance to identify target populations for cholera vaccination and requesting vaccines through the ICG mechanism in acutely limited supply.
February 9, 2023 - The WHO reported two OCV vaccination campaigns had been conducted across 21 districts in Malawi since the onset of the outbreak. A total of 1,947,696 doses were received as the first batch. A second request for OCV was submitted to the ICG in October 2022, and 2,941,982 doses were approved for a single-dose campaign.
December 5, 2022 - The U.S. CDC published: Travelers Returning to the U.S. with Cholera – Information and CDC Guidance for Healthcare Providers.
November 29, 2022 - About two million doses of OCVs arrived in Damascus, Syria.
November 10, 2022 - The WHO supported the Minister of Public Health of Lebanon in securing a shipment of 600,000 cholera vaccine doses from the ICG.
October 19, 2022 - The WHO Director-General stated four agencies decided to suspend the two-dose OCV vaccination strategy in favor of a one-dose approach so that more people receive some protection from limited stocks.